Well well well....
A recent study suggests that androgen receptor (AR) inhibition in prostate cancer may enhance immune system recognition of tumor cells. Standard treatments like androgen deprivation therapy (ADT) and AR signaling inhibitors (ARSi) not only slow cancer growth but also increase MHC-I molecules, which help immune cells identify and attack cancer. Prostate cancer has traditionally been resistant to immunotherapy, but these findings indicate that AR inhibition might make tumors more responsive. If confirmed in clinical trials, combining hormonal therapy with immunotherapy could improve treatment outcomes.
Prostate Cancer Highlights from ESMO23
Yale develops new form of Immunotherapy...
Statin use and mortality risk in men on ADT.
